Bupropion for Substance Use Disorders
Bupropion (Wellbutrin) is FDA-approved and guideline-recommended specifically for nicotine/tobacco use disorder, with emerging evidence supporting its use for methamphetamine use disorder, particularly in males with low-to-moderate use patterns. For other substance use disorders, the evidence is limited and off-label use should be approached cautiously.
Primary Indication: Nicotine/Tobacco Use Disorder
Bupropion is a preferred first-line pharmacotherapy for smoking cessation 1. The NCCN guidelines position it alongside varenicline and combination nicotine replacement therapy as standard treatment options.
Dosing for Smoking Cessation
- Initiate 1-2 weeks prior to quit date
- Days 1-3: 150 mg once daily
- Day 4 through 7-12 weeks: 150 mg twice daily (maximum 300 mg/day)
- Therapy may be extended to 6-12 months to promote continued cessation 1
Efficacy
Bupropion demonstrates well-established efficacy for nicotine dependence when combined with behavioral counseling 2. A large multicenter RCT found no increased neuropsychiatric adverse events compared to nicotine patches or placebo, even in patients with diagnosed psychiatric disorders 1.
Emerging Indication: Methamphetamine Use Disorder
For methamphetamine use disorder, bupropion shows promise, particularly in specific subpopulations. A 2023 meta-analysis found bupropion reduced amphetamine-type stimulant use (RR: 0.90) and craving, with greater effects in 12-week trials and male-only samples 3.
The most compelling evidence comes from a 2008 study showing bupropion was effective for increasing abstinence weeks specifically in male patients with low-to-moderate baseline methamphetamine use (p<0.0001), when combined with behavioral group therapy 4. Recent data from the ADAPT-2 trial demonstrated that combined naltrexone plus bupropion produced a 27.1% increase in methamphetamine-negative urine screens over 12 weeks 5.
Clinical Pearl: Bupropion appears most effective for methamphetamine use disorder in males with lower baseline use patterns, not heavy users 4.
Limited Evidence: Other Substance Use Disorders
Cocaine Use Disorder
Small studies suggest potential benefit when combined with relapse prevention therapy, particularly in patients with comorbid ADHD 6. However, no medication-assisted therapy has been definitively established as effective for cocaine use disorder 7.
Alcohol and Opioid Use Disorders
Bupropion is NOT recommended as monotherapy for these conditions. A 2026 case series described benefit of dextromethorphan-bupropion combination in dual-diagnosis depression with alcohol/opioid dependence 8, but this represents preliminary data only.
The AGA guidelines note that naltrexone-bupropion ER showed reduction in nicotine use and weight gain mitigation in obesity patients attempting smoking cessation 9, but this combination is not FDA-approved for substance use disorder treatment.
Critical Contraindications
Bupropion is absolutely contraindicated in 10:
- Seizure disorders (lowers seizure threshold)
- Current or prior bulimia or anorexia nervosa
- Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
- Concurrent MAOI use (within 14 days)
- Patients with brain metastases or stroke 1
Additional cautions 1:
- Uncontrolled hypertension
- Concurrent tamoxifen use
- Closed-angle glaucoma
- Patients requiring opioid therapy (when using naltrexone-bupropion combination) 9
Neuropsychiatric Monitoring
While bupropion carries a black box warning for suicidal ideation in young adults, large trials found no increased rates of depression or suicidality compared to placebo 1. However, monitor for:
- Development or worsening of depression
- Suicidal ideation/behavior (especially in patients <24 years)
- Hostility or agitation
- Discontinue immediately if these symptoms emerge 1
Special Populations
Adolescents (10-18 years)
The 2025 American Thoracic Society guideline suggests a trial of bupropion for adolescent nicotine use (conditional recommendation, very low-certainty evidence) 11. Bupropion SR at 300 mg/day appears well-tolerated in adolescents, though abstinence rates are lower than in adults 11. One study showed benefit in substance-abusing adolescents with comorbid ADHD and mood disorders 12.
Renal/Hepatic Impairment
- Moderate-severe renal impairment: Reduce dose by 50%
- End-stage renal disease: Avoid use
- Moderate-severe hepatic impairment: Maximum 150 mg daily 9
Clinical Algorithm for Use
- First-line use: Nicotine/tobacco use disorder in any patient without contraindications
- Consider for: Methamphetamine use disorder in males with low-to-moderate use patterns
- May consider for: Cocaine use disorder with comorbid ADHD (off-label, limited evidence)
- Avoid as monotherapy for: Alcohol use disorder, opioid use disorder
- Reassess at 12 weeks: If <5% improvement in substance use outcomes, discontinue as patient is likely a poor responder 9
Common Pitfalls
- Do not use in patients with seizure risk factors - this is the most critical safety concern
- Do not combine with opioids when using naltrexone-bupropion formulations
- Do not expect efficacy in heavy methamphetamine users - evidence supports use only in low-to-moderate use patterns
- Do not use as sole treatment - always combine with behavioral therapy for optimal outcomes 4, 2